This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HALLORAN, B. P. Articles by GOLDSMITH, R. S. Search for Related Content PubMed PubMed Citation Articles by HALLORAN, B. P. Articles by GOLDSMITH, R. S.

Plasma Vitamin D Metabolite Concentrations in Chronic Renal Failure: Effect of Oral Administration of 25-Hydroxyvitamin D3^*

Department of Medicine, University of California and Veterans Administration Medical Center San Francisco, California, 94121
University of Texas Health Science Center and Audie L. Murphy Memorial Veterans Administration Hospital San Antonio, Texas 78284

Address correspondence and requests for reprints to: Bernard Halloran, Veterans Administration Medical Center (11), 4150 Clement Street, San Francisco, California 94121.

The circulating concentrations of 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D are abnormally low in patients with chronic renal failure (CRF). To determine the importance of substrate (25-hydroxyvitamin D) concentration in this phenomenon, five patients with end stage renal disease treated with hemodialysis were given 25-hydroxyvitamin D₃ (25-OH-D₃) orally for 4 weeks. The serum concentration of 25-OH-D₃ increased from a mean (±SEM) of 26 ± 5 ng/ml immediately before therapy to a maximum of 108 ± 5 ng/ml 4 weeks after beginning administration of 25-OH-D₃. The concentrations of 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), 24,25-dihydroxyvitamin D₃ (24,25(OH)₂D₃), and 25,26-dihydroxyvitamin D₃ (25,26(OH)₂D₃) increased from 6.6 ± 0.8 pg/ml, 0.29 ± 0.10 ng/ml, and 0.36 ± 0.06 ng/ml, respectively, immediately before 25-OH-D₃ administration to 21.7 ± 2.2 pg/ml, 0.48 ± 0.09 ng/ ml; and 0.78 ± 0.12 ng/ml, respectively, after 4 weeks of administration of 25-OH-D₃. These results suggest that substrate availability may be an important determinant of the circulating concentrations of these metabolites in patients with CRF. It seems possible that the therapeutic effects of 25-OH-D₃ administration to the CRF patient may be mediated through the normal actions of 1,25-dihydroxyvitamin D₃, 24,25-dihydroxyvitamin D₃, and perhaps other metabolites rather than through analog effects of 25-OH-D₃.

^* Supported in part by the Veterans Administration and Grant AM-27112 from the NIH.

Received December 1, 1983.

This article has been cited by other articles:

				G. Jean, J.-C. Souberbielle, and C. Chazot Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3799 - 3805. [Abstract] [Full Text] [PDF]

				F. N. Ali, L. M. Arguelles, C. B. Langman, and H. E. Price Vitamin D Deficiency in Children With Chronic Kidney Disease: Uncovering an Epidemic Pediatrics, March 1, 2009; 123(3): 791 - 796. [Abstract] [Full Text] [PDF]

				D. C. Huang, V. Papavasiliou, J. S. Rhim, R. L. Horst, and R. Kremer Targeted Disruption of the 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Gene in ras-Transformed Keratinocytes Demonstrates That Locally Produced 1{alpha},25-Dihydroxyvitamin D3 Suppresses Growth and Induces Differentiation in an Autocrine Fashion Mol. Cancer Res., November 1, 2002; 1(1): 56 - 67. [Abstract] [Full Text] [PDF]

				G. K. Fu, D. Lin, M. Y. H. Zhang, D. D. Bikle, C. H. L. Shackleton, W. L. Miller, and A. A. Portale Cloning of Human 25-Hydroxyvitamin D-1{alpha}-Hydroxylase and Mutations Causing Vitamin D-Dependent Rickets Type 1 Mol. Endocrinol., December 1, 1997; 11(13): 1961 - 1970. [Abstract] [Full Text] [PDF]

				S. Kamimura, M. Gallieni, M. Zhong, W. Beron, E. Slatopolsky, and A. Dusso Microtubules Mediate Cellular 25-Hydroxyvitamin D(3) Trafficking and the Genomic Response to 1,25-Dihydroxyvitamin D(3) in Normal Human Monocytes J. Biol. Chem., September 22, 1995; 270(38): 22160 - 22166. [Abstract] [Full Text] [PDF]